Skip to main content

Table 1 Baseline characteristics of the BRCA patients between the low and high-risk groups in different cohorts

From: The integration of multidisciplinary approaches revealed PTGES3 as a novel drug target for breast cancer treatment

Characteristic

TCGA-BRCA cohort

METABRIC cohort

GSE86166 cohort

Low risk

High risk

p

Low risk

High risk

p

Low risk

High risk

p

Age (mean (SD))

56.34(12.78)

59.90(12.72)

0.001

60.78 (12.26)

60.61 (13.70))

0.87

   

 M (%)

  

0.492

      

  M0

268(90.2)

262(88.5)

       

  M1

4(1.3)

8(2.7)

       

  MX

25(8.4)

26(8.8)

       

N (%)

  

0.041

      

 N0

140(47.1)

134(45.3)

       

 N1

106(35.7)

91(30.7)

       

 N2

30(10.1)

47(15.9)

       

 N3

19(6.4)

15(5.1)

       

 NX

2(0.7)

9(3.0)

       

 T (%)

  

0.008

      

  T1

95(32.0)

57(19.3)

       

  T2

164(55.2)

194(65.5)

       

  T3

29(9.8)

31(10.5)

       

  T4

9(3.0)

13(4.4)

       

  TX

0(0.0)

1(0.3)

       

 Grade (%)

     

 < 0.001

  

0.002

 G1

   

62(10.2)

43(6.6)

 

25(13.7)

11(6.0)

 

 G2

   

272(44.9)

209(32.1)

 

85(46.4)

63(34.4)

 

 G3

   

272(44.9)

400(61.3)

 

66(36.1)

102(55.7)

 

 G4

      

6(3.3)

5(2.7)

 

 G5

      

1(0.5)

2(1.1)

 

Tumor size (mean (SD))

   

24.72 (12.85)

27.12 (16.68)

0.005

   

 Stage (%)

  

0.143

  

0.714

  

0.221

  Unknown

   

0(0.0)

1(0.2)

 

7(3.8)

3(1.6)

 

  Stage I

55(18.5)

37(12.5)

 

212(35.0)

210(32.2)

 

2(1.1)

2(1.1)

 

  Stage II

175(58.9)

172(58.1)

 

341(56.3)

378(58.0)

 

62(33.9)

49(26.8)

 

  Stage III

61(20.5)

76(25.7)

 

50(8.3)

59(9.0)

 

84(45.9)

92(50.3)

 

  Stage IV

4(1.3)

6(2.0)

 

3(0.5)

4(0.6)

    

  Stage X

2(0.7)

5(1.7)

       
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us